RenDx open access technology
The technology behind the RenDx Multiplex Assay system can be applied to nucleic acid detection in a range of research areas and applications. Renishaw will be happy to discuss development and/or licensing agreements in order to facilitate such R&D projects.
Case Study: Human Papilloma Virus
Human Papilloma Virus (HPV) is a DNA virus classified in the Papillomaviridae family. There are more than two hundred known HPV genotypes, the majority of which are classified as low risk (LR) and present minimal or no risk to their human host. However, high risk (HR) genotypes are oncogenic and persistent infection can cause cervical cancer, with approximately 99% of all invasive cervical carcinomas harbouring at least one type of HR HPV.
A recently published paper illustrates the successful transfer of an HPV genotyping assay to the RenDx RUO platform. Using previously validated PCR primers and probes, researchers at Cardiff University reported the use of SERRS detection to screen across six channels, including: four unique high risk HPV types (16/18/31/45); other HR types; and other LR types. Twenty five clinical samples were tested in this initial study of which twenty three gave the expected results with samples classified as LR HPV and HR HPV negative or positive.
This approach provides a significant advantage over fluorescence/QPCR assays which have limited multiplexing capabilities. SERS has allowed identification and differentiation of HR and LR genotypes, critical to choosing the most appropriate patient management. Without this type specific information, healthcare providers are at risk of either over-burdening patients at minimal risk of cancer or under-treating high-risk individuals.
Publications and articles
Analytical Methods Paper - Anal. Methods, 2014, 6, 1288-1290
Chemistry World Article - Catching viruses associated with cervical cancer